NanoSpark STEM-T T Cell Activator Enhances Stem-like Boosts CD8+ T Cell Populations

Cellular therapies are the cancer treatment of the future. Chimeric antigen receptor (CAR) T cell therapy has been a revolutionary advancement in cell and gene therapy and is currently, the most clinically and commercially advanced cell therapy. Despite their effectiveness, these therapies have encountered some obstacles including manufacturing failures, long manufacturing times, and short-lived or poor treatment outcomes. One solution to these challenges is optimizing the activation and expansion step of the manufacturing process. Nanotein’s novel platform technology NanoSpark^®, armed with anti-CD3 and anti-CD28 antibodies, is a soluble reagent that promotes the growth of stem-like, less differentiated T cells with a bias towards clinically relevant CD8+ stem cell-like memory T cells (Tscm) during 7 to 10-day expansions of donor T cells. These cells are long-lived, with high proliferative potential, and are capable of further differentiation and self renewal, which can produce more durable responses in patients.